摘要
目的探讨非小细胞肺癌(NSCLC)患者病程中血管生成素2(Ang2)和血管内皮生长因子(VEGF)的变化情况,评价在肿瘤发生、进展、预后的临床意义。方法对82例首诊未经治疗的NSCLC患者行ELISA法定量检测外周血Ang2与VEGF水平。结果 NSCLC患者外周血Ang2与VEGF水平较对照组明显升高[Ang2:(1326.8±942.9)pg/mlvs.(445.0±213.0)pg/ml,P<0.01;VEGF:(846.8±459.6)pg/mlvs.(691.3±369.6)pg/ml,P<0.05]。Ang2在早期NSCLC开始明显升高,但在各进展期之间比较差异无统计学意义,进入晚期后在越接近死亡的患者Ang2又再有上升趋势。VEGF在早期未见升高,进入进展期后逐渐升高,在未有远处转移的患者,原发灶直径越大,VEGF越高。COX回归分析显示临床分期与VEGF是NSCLC生存预后的独立危险因素(P<0.05)。结论 NSCLC患者血清Ang2与VEGF均明显升高,对早期NSCLC患者检测血清Ang2较VEGF有更好的辅助诊断价值,在NSCLC进展期检测血清VEGF较Ang2更有助于评价肿瘤进展情况,在NSCLC晚期检测血清Ang2升高较VEGF更能提示临终期。
Objective To investigate the serum concentrations of Ang2 and VEGF in patients with NSCLC,and to provide some guidances in early diagnosis,progression evaluation and prognosis prediction for NSCLC.Methods A total of 82 patients with untreated NSCLC were selected,ELISA was used to measure the serum VEGF and Ang2 levels in all cases.Results Ang2 and VEGF levels in NSCLC group were significantly higher than those in the control group [Ang2：（1326.8 ± 942.9）pg/ml vs.（445.0 ± 213.0） pg/ml,P0.01;VEGF：（846.8 ± 459.6）pg/ml vs.（691.3 ± 369.6） pg /ml,P0.05].Serum Ang2 significantly increased in the early stage and terminal advanced stage of NSCLC,but showed no difference among various advanced subgroups.Serum VEGF levels began to increase with the progression of TNM staging from mid-stage,but not in early stage NSCLC,The diameter of intrapulmonary primary tumor was positively correlated with the serum VEGF levels in non-metastatic NSCLC.COX regression analysis showed that TNM staging and VEGF levels were independent risk factors on survival prognosis（P0.05）.Conclusion Serum Ang2 and VEGF levels were significantly higher in NSCLC.Detecting serum Ang2 is more valuable for aiding early diagnosis than VEGF.Serum VEGF can be used to evaluate tumor progression better than Ang2 in the advanced stage NSCLC.An elevation in Ang2 in a late stage can show that the patient has entered a terminal stage.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2011年第1期83-86,共4页
Cancer Research on Prevention and Treatment
关键词
非小细胞肺癌
血管生成素2
血管内皮生长因子
Non-small cell lung cancer（NSCLC）
Angiopoietin 2（Ang2）
Vascular endothelial growth factor（VEGF）
